Synthesis and preliminary in vivo evaluation of 4-[18F]fluoro-N- {2-[4-(6-trifluoromethylpyridin-2-yl) piperazin-1-yl]ethyl}benzamide, a potential PET radioligand for the 5-HT1A receptor

Journal of Labelled Compounds and Radiopharmaceuticals

Volumn 47, Issue 9, 2004, Pages 531-542

  Vandecapelle, M ^a,e   Dumont, F ^a   De Vos, F ^b   Strijckmans, K ^c   Leysen, D ^d   Audenaert, K ^b   Dierckx, R A ^b   Slegers, G ^a  

^a GHENT UNIVERSITY   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d NV ORGANON   (Netherlands)

^e NONE   (Belgium)

Author keywords

5 HT1A agonist; 18F labelling; Biodistribution study; Org 13063

Indexed keywords

ISOTOPES;

18F LABELING; 5-HT1A AGONIST; BENZAMIDES; BIODISTRIBUTION STUDY; BIODISTRIBUTIONS; IN-VIVO; LABELINGS; ORG 13063; PET RADIOLIGAND; VIVO EVALUATION;

AMIDES;

4 FLUORO N [2 [4 (6 TRIFLUOROMETHYLPYRIDIN 2 YL)PIPERAZIN 1 YL]ETHYL]BENZAMIDE C 14; BENZAMIDE DERIVATIVE; PIPERAZINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT; SEROTONIN 1A RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISTRIBUTION; DRUG SYNTHESIS; DRUG UPTAKE; FLUORINATION; ISOTOPE LABELING; MALE; MICROWAVE IRRADIATION; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REACTION ANALYSIS;

EID: 4344667940     PISSN: 03624803     EISSN: None     Source Type: Journal    
DOI: 10.1002/jlcr.837     Document Type: Article

References (22)

1. Borne RF. Drugs Top 1994; 138: 108-117.
2. Ögren SO, Misane I. Nucl Med Biol 1998; 25: 747-749.
3. Saxena PR. Pharmacol Ther 1995; 66: 339-368.
4. De Vry J. Psychopharmacologia 1995; 121: 1-26.
5. Wilson AA, Inaba T, Fischer N, Dixon LM, Nobrega J, DaSilva JN, Houle S. Nucl Med Biol 1998; 25: 769-776.
6. Pike VW, McCarron JA, Lammertsma AA, Osman S, Hume SP, Sargent PA, Bench CJ, Cliffe IA, Fletcher A, Grasby PM. Eur J Pharm 1996; 301: R5-R7.
7. Pike VW, Halldin C, McCarron JA, Lundkvist C, Hirani E, Olsson H, Hume SP, Karlsson P, Osman S, Swahn CG, Hall H, Wikström H, Mensonidas M, Poole KG, Farde L. Eur J Nucl Med 1998; 25: 338-346.
8. Andrée B, Halldin C, Pike VW, Gunn RN, Olsson H, Farde L. J Nucl Med 2002; 43: 292-303.
9. Passchier J, van Waarde A, Pieterman RM, Elsinga PH, Hendrikse HN, Pruim J, Willemsen AT, Vaalburg W. J Nucl Med 1999; 40(5)(Suppl.): 29.
10. Plenevaux A, Lemaire C, Salmon E, Laureys S, Fuchs S, Maquet P, Degueldre C, Aerts J, Brihaye C, Damhaut P, Biver F, Goldman S, Le Bars D, Ginovart N, Cinotti L, Pujol JF, Luxen A. J Label Compd Radiopharm 1999; 42(Suppl. 1): S60-S62.
11. Sanabria-Bohorquez SM, Biver F, Damhaut P, Wikler D, Veraart C, Goldman S. Eur J Nucl Med 2002; 29: 76-81.
12. Halldin C, Sandell J, Chou YH, Hall H, Thorberg SO, Werner T, Schwahn CG, Farde L. J Nucl Med 1999; 40(5)(Suppl.): 38.
13. Sandell J, Halldin C, Chou YH, Schwahn G, Thorberg SO, Sohn D, Werner T, Farde L. J Label Compd Radiopharm 1999; 42(Suppl. 1): S675-S677.
14. Sandell J, Halldin C, Chou YH, Swahn CG, Thorberg SO, Farde L. Nucl Med Biol 2002; 29: 39-45.
15. G. Walker, Organon NV, Newhouse. Personal Communication.
16. Vandecapelle M, De Vos F, Dumont F, Audenaert K, Leysen D, Dierckx RA, Slegers G. J Label Compd Radiopharm 2001; 44: 73-88.
17. Vandecapelle M, De Vos F, Vermeirsch H, De Ley G, Audenaert K, Leysen D, Dierckx RA, Slegers G. Nucl Med Biol 2001; 28: 639-643.
18. Visser GM, van Waarde A, Medema J, Vaalburg W. J Label Compd Radiopharm 1995; 37: 280-282.
19. Suehiro M, Underwood M, Arango V, Wang TS, Kassir S, Bakalian M, Yatabe T, Pratap M, Van Heertum RL, Mann JJ. Life Sci 1998; 63: 1533-1542.
20. Zimmer L, Fournet G, Joseph B, Guillaumet G, Le Bars D. Nucl Med Biol 2003; 30: 541-546.
21. Passchier J, van Waarde A. Eur J Nucl Med 2001; 28: 113-129.
22. 1A receptors in vivo. In Progress in Medicinal Chemistry, King FD, Oxford AW (eds). Elsevier Science: Oxford, 2001; 189-247.